Provided by Tiger Fintech (Singapore) Pte. Ltd.

EyePoint

6.58
+0.50008.22%
Post-market: 6.45-0.1300-1.98%19:34 EST
Volume:963.28K
Turnover:6.12M
Market Cap:449.09M
PE:-3.22
High:6.61
Open:6.33
Low:5.94
Close:6.08
Loading ...

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
16 Jan

EyePoint Pharmaceuticals Inc: Cash Runway Into 2027 Beyond Topline Duravyu Phase 3 Wet Amd Data Expected in 2026

THOMSON REUTERS
·
13 Jan

EyePoint Pharmaceuticals: Full Data for Phase 2 Verona Clinical Trial of Duravyu in Dme Expected in 1Q 2025

THOMSON REUTERS
·
13 Jan

EyePoint Provides Company Update and Anticipated Development Milestones for 2025

GlobeNewswire
·
13 Jan

Optimistic Buy Rating for EyePoint Pharmaceuticals: Potential of Duravyu in Diabetic Macular Edema

TIPRANKS
·
09 Jan

EyePoint Pharmaceuticals Strengthens Board with New Appointment

TIPRANKS
·
08 Jan

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.d., Fasrs to Board of Directors

THOMSON REUTERS
·
08 Jan

Press Release: EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors

Dow Jones
·
08 Jan

Citigroup Initiates EyePoint Pharmaceuticals at Buy With $33 Price Target

MT Newswires Live
·
07 Jan

Positive Outlook for EyePoint Pharmaceuticals Driven by Promising Prospects in the DME Market

TIPRANKS
·
03 Jan

EyePoint reports inducement grants under NASDAQ listing rule

TipRanks
·
17 Dec 2024

BRIEF-Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule

Reuters
·
16 Dec 2024

EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
16 Dec 2024

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
16 Dec 2024

EyePoint Pharmaceuticals Price Target Maintained With a $22.00/Share by HC Wainwright & Co.

Dow Jones
·
05 Dec 2024

EyePoint doses first patient in second Phase 3 LUCIA clinical trial

TIPRANKS
·
04 Dec 2024